Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALEO: Chemoradioimmunotherapy in Esophageal Cancer
NCT06290505Phase 2Recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Dec 2021
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
A Phase 2 trial of durvalumab in esophageal cancer, sponsored by Australasian Gastro-Intestinal Trials Group. Started Dec 2021; status: recruiting.
02
Drugs
durvalumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT06290505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290505.